Efavirenz

Generic Name
Efavirenz
Brand Names
Atripla, Stocrin, Sustiva, Symfi, Efavirenz Teva
Drug Type
Small Molecule
Chemical Formula
C14H9ClF3NO2
CAS Number
154598-52-4
Unique Ingredient Identifier
JE6H2O27P8
Background

Efavirenz (brand names Sustiva® and Stocrin®) is a non-nucleoside reverse transcriptase inhibitor (NNRTI) and is used as part of highly active antiretroviral therapy (HAART) for the treatment of a human immunodeficiency virus (HIV) type 1.
...

Indication

For use in combination treatment of HIV infection (AIDS)

Associated Conditions
Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Associated Therapies
-
Clinical Trials
Related News

Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults

First Posted Date
2005-07-12
Last Posted Date
2018-10-12
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
1864
Registration Number
NCT00118898
Locations
🇺🇸

Univ of Iowa Hosp and Clinic (1504), Iowa City, Iowa, United States

🇺🇸

Vanderbilt Therapeutics CRS (3652), Nashville, Tennessee, United States

🇺🇸

SUNY - Buffalo (Rochester) (1102), Buffalo, New York, United States

and more 49 locations

Efficacy of Tenofovir-Emtricitabine and Efavirenz in HIV Infected Patients With Tuberculosis (ANRS129)

Phase 3
Completed
Conditions
HIV Infections
Tuberculosis
First Posted Date
2005-06-24
Last Posted Date
2011-12-22
Lead Sponsor
French National Agency for Research on AIDS and Viral Hepatitis
Target Recruit Count
70
Registration Number
NCT00115609
Locations
🇫🇷

Service des maladies Infectieuses et tropicales Hopital Necker-Enfants Malades, Paris, France

A Study of TMC278 in Human Immunodeficiency Virus Type 1 Infected Patients, Who Are Not Treated With Antiretroviral Medicines

First Posted Date
2005-05-06
Last Posted Date
2014-06-25
Lead Sponsor
Tibotec Pharmaceuticals, Ireland
Target Recruit Count
368
Registration Number
NCT00110305

Anti-HIV Drugs for Treating Infants Who Acquired HIV Infection at Birth

First Posted Date
2005-02-07
Last Posted Date
2021-11-02
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
377
Registration Number
NCT00102960

Effects of Anti-HIV Therapy on Treatment for Hepatitis C in HCV/HIV Infected Adults

Not Applicable
Completed
Conditions
HIV Infections
Hepatitis C
First Posted Date
2005-01-04
Last Posted Date
2021-11-01
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
2
Registration Number
NCT00100581
Locations
🇺🇸

Columbia Univ., HIV Prevention and Treatment Medical Ctr., New York, New York, United States

🇺🇸

Univ. of Texas Southwestern Med. Ctr., Amelia Court Continuity Clinic, Dallas, Texas, United States

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected People in Wenxi County, Shanxi Province, China

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2005-01-04
Last Posted Date
2011-02-23
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
100
Registration Number
NCT00100594

Efavirenz and Lamivudine/Zidovudine for Treatment-Naive HIV Infected Adults in Senegal

Not Applicable
Completed
Conditions
HIV Infections
Interventions
Drug: Efavirenz
Drug: Lamivudine/zidovudine
First Posted Date
2005-01-04
Last Posted Date
2013-09-06
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
44
Registration Number
NCT00100568
Locations
🇸🇳

Centre National Hospitalier de Fann, Dakar CIPRA CRS, Dakar, Senegal

🇸🇳

Institut d'Hygiène Sociale, Dakar CIPRA CRS, Dakar, Senegal

Effectiveness of Directly Observed Therapy in Combined HIV and Tuberculosis Treatment in Resource-limited Settings

Not Applicable
Completed
Conditions
HIV Infections
Tuberculosis
First Posted Date
2004-09-21
Last Posted Date
2010-03-29
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
592
Registration Number
NCT00091936
Locations
🇿🇦

King Edward VIII Hospital, Congella, Durban, South Africa

🇿🇦

Prince Cyril Zulu CDC, Congella, Durban, South Africa

Prospective Evaluation of Anti-retroviral Combinations for Treatment Naive, HIV Infected Persons in Resource-limited Settings

First Posted Date
2004-06-08
Last Posted Date
2018-10-10
Lead Sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Target Recruit Count
1571
Registration Number
NCT00084136
Locations
🇺🇸

University of Texas, Galveston, Galveston, Texas, United States

🇲🇼

College of Med. JHU CRS, P.O. Box 1131, Blantyre, Malawi

🇿🇼

UZ-Parirenyatwa CRS, AIDS Research Unit P.O. Box A178, Harare, Zimbabwe

and more 39 locations

Strategies for Delivering Anti-HIV Therapy in South Africa

Not Applicable
Completed
Conditions
HIV Infections
First Posted Date
2004-04-07
Last Posted Date
2007-09-18
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Target Recruit Count
813
Registration Number
NCT00080522
Locations
🇿🇦

University of the Witwatersrand/Clinical HIV Research Unit, Johannesburg, Gauteng, South Africa

🇿🇦

University of Cape Town/Masiphumelele, Cape Town, South Peninsula, South Africa

© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy